Bone Substitutes in Management of Benign Bone Tumors, Review of Literature
Main Article Content
Abstract
Intralesional excision or curettage is commonly used to treat benign and low-grade malignant bone tumors. The resulting defect can be treated with a variety of materials, such as autologous bone grafts, allografts, or synthetic materials like polymethylmethacrylate or composite alternatives. Because it is osteogenic, osteoinductive, and osteoconductive, autologous cancellous bone is often considered the gold standard of transplant material. However, issues including transplant size limitations, wound-related complications, and prolonged donor site pain have limited its usage in clinical practice. Concerns about immunogenicity and infection have also hampered the use of demineralized freeze-dried allografts and xenografts. As a result, synthetic materials have sparked substantial interest in orthopedics, and a variety of bone graft alternatives are now commercially accessible.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
- Kotrych, D., Korecki, S., Ziętek, P., Kruk, B., Kruk, A., Wechmann, M., ... & Bohatyrewicz, A. (2018). Preliminary results of highly injectable bi-phasic bone substitute (CERAMENT) in the treatment of benign bone tumors and tumor-like lesions. Open Medicine, 13(1), 487-492.
- Del Regno, C., Fanfani, F., Morini, A., Marsico, A., Piccioli, A., & Maccauro, G. (2013). DIFFERENT TREATMENT MODALITIES OF HAND ENCHONDROMAS: A REVIEW OF THE LITERATURE. Journal of Orthopedics, 5(2).
- Hinsenkamp, M., Muylle, L., Eastlund, T., Fehily, D., Noël, L., & Strong, D. M. (2012). Adverse reactions and events related to musculoskeletal allografts: reviewed by the World Health Organisation Project NOTIFY. International orthopedics, 36, 633-641.
- Kinaci, A., Neuhaus, V., & Ring, D. C. (2014). Trends in bone graft use in the United States. Orthopedics, 37(9), e783-e788.
- Horstmann, P. F., Hettwer, W. H., & Petersen, M. M. (2018). Treatment of benign and borderline bone tumors with combined curettage and bone defect reconstruction. Journal of Orthopaedic Surgery, 26(3), 2309499018774929.
- Bhatt, R. A., & Rozental, T. D. (2012). Bone graft substitutes. Hand Clinics, 28(4), 457-468.
- Fernandez de Grado, G., Keller, L., Idoux-Gillet, Y., Wagner, Q., Musset, A. M., Benkirane-Jessel, N., ... & Offner, D. (2018). Bone substitutes: a review of their characteristics, clinical use, and perspectives for large bone defects management. Journal of Tissue Engineering, 9, 2041731418776819
- Bi, Y., Stuelten, C. H., Kilts, T., Wadhwa, S., Iozzo, R. V., Robey, P. G., ... & Young, M. F. (2005). Extracellular matrix proteoglycans control the fate of bone marrow stromal cells. Journal of Biological Chemistry, 280(34), 30481-30489
- Valtanen, R. S., Yang, Y. P., Gurtner, G. C., Maloney, W. J., & Lowenberg, D. W. (2021). Synthetic and Bone tissue engineering graft substitutes: What is the future? Injury, 52, S72-S77.
- Zimmermann, G., & Moghaddam, A. (2011). Allograft bone matrix versus synthetic bone graft substitutes. Injury, 42, S16-S21.
- Campana, V., Milano, G. I. U. S. E. P. P. E., Pagano, E., Barba, M., Cicione, C., Salonna, G., ... & Logroscino, G. (2014). Bone substitutes in orthopedic surgery: from basic science to clinical practice. Journal of Materials Science: Materials in Medicine, 25, 2445-2461
- Urist, M. R., Mikulski, A., & Boyd, S. D. (1975). A chemo-sterilized antigen-extracted autodigested alloimplant for bone banks. Archives of Surgery, 110(4), 416-428.
- Roberts, T. T., & Rosenbaum, A. J. (2012). Bone grafts, bone substitutes, and orthobiologics: the bridge between basic science and clinical advancements in fracture healing. Organogenesis, 8(4), 114-124.
- Iwatsu, J., Watanuki, M., Yoshida, S., Hitachi, S., Watanabe, M., & Aizawa, T. (2022). Clinical outcome of porous hydroxyapatite/collagen graft on bone defects following curettage of bone tumors. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 110(10), 2211-2216.
- Chai, F., Raoul, G., Wiss, A., Ferri, J., & Hildebrand, H. F. (2011). Bone substitutes: classification and concerns. Revue de Stomatologie et de Chirurgie Maxillo-faciale, 112(4), 212-221.
- Hak D. J. (2007). The use of osteoconductive bone graft substitutes in orthopedic trauma. The Journal of the American Academy of Orthopaedic Surgeons, 15(9), 525–536. https://doi.org/10.5435/00124635-200709000-00003
- Bohner, M. (2010). Design of ceramic-based cement and putties for bone graft substitution. Eur Cell Mater, 20(1), 3-10.
- Wahyudi, B., Muljani, S., Alfan, M. A., & Zukhrufiansyah, A. R. (2020, July). Synthesis and Characteristics of β-Tri-Calcium Phosphate from Green Mussel Shell. In Journal of Physics: Conference Series (Vol. 1569, No. 4, p. 042056). IOP Publishing.
- Deng, K., Liu, Z., Dou, W., Cai, Q., Ma, W., & Wang, S. (2022). HA/β-TCP Biphasic Calcium Phosphate Ceramics Derived From Butterfish Bones Loaded With Bone Marrow Mesenchymal Stem Cells Promote Osteogenesis. Frontiers in Materials, 9, 928075...
- Zrodowski, M., Ciechanowicz, D., Dembski, M., Piotrowicz, M., Napora, J., & Mazurek, T. (2022). The use of bone substitute (CERAMENT) in the treatment of benign bone tumors and tumor-like lesions. Chirurgia Narządów Ruchu i Ortopedia Polska, 87(1), 1-7.
- Hofmann, A., Gorbulev, S., Guehring, T., Schulz, A. P., Schupfner, R., Raschke, M., ... & Rommens, P. M. (2020). Autologous iliac bone graft compared with biphasic hydroxyapatite and calcium sulfate cement for the treatment of bone defects in tibial plateau fractures: a prospective, randomized, open-label, multicenter study. The Journal of Bone and Joint Surgery. American Volume, 102(3), 179
- Döring, K., Rentenberger, C., Kolb, A., Patsch, J., Puchner, S., Windhager, R., & Chiari, C. (2022). Treatment of benign bone lesions with an injectable biphasic bone substitute. BMC Musculoskeletal Disorders, 23(1), 901.
- Razii, N., Docherty, L. M., Halai, M., Mahendra, A., & Gupta, S. (2023). Injectable Synthetic Beta-Tricalcium Phosphate/Calcium Sulfate (GeneX) for the Management of Contained Defects Following Curettage of Benign Bone Tumours. Current Oncology (Toronto, Ont.), 30(4), 3697–3707. https://doi.org/10.3390/curroncol30040281
- Wittig, U. S., Friesenbichler, J., Liegl-Atzwanger, B., Igrec, J., Andreou, D., Leithner, A., & Scheipl, S. (2023). Artificial Bone Graft Substitutes for Curettage of Benign and Low-Grade Malignant Bone Tumors: Clinical and Radiological Experience with Cerasorb. Indian journal of orthopedics, 57(9), 1409–1414. https://doi.org/10.1007/s43465-023-00919-1
- Gava, N. F., & Engel, E. E. (2022). Treatment alternatives and clinical outcomes of bone filling after benign tumor curettage. A systematic review. Orthopaedics & traumatology, surgery & research : OTSR, 108(4), 102966. https://doi.org/10.1016/j.otsr.2021.102966